个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Sun, Jian[1] * ; Ding, Huiguo[2] ; Chen, Guofeng[3] ; Wang, Guiqiang[4] ; Wei, Lai[5] ; Zhang, Jiming[6] ; Xie, Qing[7] ; Wan, Mobin[8] ; Tang, Hong[9] ; Chen, Shijun[10] ; Gao, Zhiliang[11] ; Wang, Yuming[12] ; Zhang, Dazhi[13] ; Huang, Wenxiang[15] ; Sheng, Jifang[16] ; Ning, Qin[17] ; Yang, Dongliang[18] ; Lu, Jian[19] ; Pan, Chen[20] ; Yang, Yuxiu[21] ; Wang, Jue[22] ; Sun, Chuanzhen[22] ; Wang, Qixin[22] ; Hou, Jinlin[1] ;
单位： [1]Southern Med Univ, State Key Lab Organ Failure Res, Guangdong Prov Key Lab Viral Hepatitis Res, Dept Infect Dis,Nanfang Hosp, Guangzhou, Guangdong, Peoples R China [2]Capital Med Univ, Beijing Youan Hosp, 8 You Men Wai St, Beijing 100069, Peoples R China [3]Beijing 302 Hosp, 100 Xi Si Huan Zhong Lu, Beijing 100039, Peoples R China [4]Peking Univ, Hosp 1, 8 Xicheng Xishiku St, Beijing 100034, Peoples R China [5]Peking Univ, Peoples Hosp, 11 Xizhimen South St, Beijing 100044, Peoples R China [6]Fudan Univ, Huashan Hosp, 12 Middle Wurumuqi Rd, Shanghai 200040, Peoples R China [7]Shanghai Jiao Tong Univ, Shanghai Ruijin Hosp, 197 Ruijiner Rd, Shanghai 200025, Peoples R China [8]Shanghai Changhai Hosp, 174 Changhai Rd, Shanghai 200433, Peoples R China [9]Sichuan Univ, Huaxi Hosp, 37 Guo Xue Xiang, Chengdu 610041, Sichuan, Peoples R China [10]Jinan Infect Dis Hosp, 173 Jingshi Rd, Jinan 250021, Shandong, Peoples R China [11]Sun Yat Sen Univ, Affiliated Hosp 3, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China [12]Third Mil Med Univ, Southwest Hosp Affiliated, 29 Gao Tan Yan Zhengjie, Chongqing 400038, Peoples R China [13]Chongqing Med Univ, Dept Infect Dis, Affiliated Hosp 2, 74 Lingjiang Rd, Chongqing, Peoples R China [14]Editing Dept Chinese Journal Hepatol, 74 Lingjiang Rd, Chongqing, Peoples R China [15]Chongqing Med Univ, Hosp1, 1 Youyi Rd, Chongqing 400016, Peoples R China [16]Zhejiang Univ, Med Coll, Affiliated Hosp 1, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China [17]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China [18]Huazhong Univ Sci & Technol, Dept Infect Dis, Union Hosp, Tongji Med Coll, 1277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China [19]Shenzhen Third Peoples Hosp, Bulan Rd 29, Shenzhen 518112, Peoples R China [20]Fuzhou Infect Dis Hosp, 312 Xihong Rd, Fuzhou 350025, Fujian, Peoples R China [21]Henan Prov Peoples Hosp, 7 Weiwu Rd, Zhengzhou 450003, Henan, Peoples R China [22]MSD China Bldg A,Headquarters Pk,Phase 2, Shanghai 200233, Peoples R China
出处：
DOI： 10.1186/s12876-019-0981-5
ISSN：

关键词： Chronic hepatitis B Peg-interferon Long-term follow-up Sustained serological response Sustained combined clinical response

摘要：
BackgroundPegylated interferon (PEG-IFN) alfa-2b is recommended for chronic hepatitis B (CHB). We aimed to investigate the sustainability of off-treatment responses among Chinese HBeAg-positive CHB patients treated with PEG-IFN alfa-2b from a randomized trial.MethodsEligible Chinese patients (n=322) were followed up by one visit after a median of 6years (LTFU) following their participation in a randomized trial evaluating the efficacy of three PEG-IFN alfa-2b dosing regimens (1.0 or 1.5g/kg/wk. 24weeks or 1.5g/kg/wk. 48weeks). Primary endpoints at the LTFU were sustained SR and CR (SR/CR at the end of original study [EOS] and at the LTFU). SR was defined as HBeAg loss and seroconversion to anti-HBe and CR as HBeAg loss and seroconversion to anti-HBe and HBV-DNA<2000IU/mL.ResultsThe proportions of patients achieving sustained SR among patients who had SR at EOS were high in three treatment groups (61.9, 65.5, 76.5%, respectively, p=0.46); treatment with PEG-IFN alfa-2b 1.5g/kg/wk. 48weeks had the highest proportion of a sustained CR among patients who had CR at EOS (75.0%, p=0.05). A considerable number of patients achieved sustained SR (18.2-29.9%) and sustained CR (14.8-18.3%) after EOS despite no further NA treatment. At the LTFU, rates of SR and CR were less than 70.0 and 50.0%, respectively, among all enrolled patients regardless of additional nucleos(t)ide analogs before the LTFU.ConclusionsPEG IFN alfa-2b therapy had considerable off-treatment sustainability in Chinese HBeAg positive chronic hepatitis B patients with serological and complete responses.

基金：
Merck Sharp & Dohme, Shanghai, China; MSD China
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类 | 3 区 医学
小类 | 4 区 胃肠肝病学
最新[2025]版：
大类 | 3 区 医学
小类 | 4 区 胃肠肝病学
JCR分区：
出版当年[2017]版：
Q3 GASTROENTEROLOGY & HEPATOLOGY
最新[2023]版：
Q3 GASTROENTEROLOGY & HEPATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者：
第一作者单位： [1]Southern Med Univ, State Key Lab Organ Failure Res, Guangdong Prov Key Lab Viral Hepatitis Res, Dept Infect Dis,Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Sun Jian,Ding Huiguo,Chen Guofeng,et al.Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China[J].BMC GASTROENTEROLOGY.2019,19:doi:10.1186/s12876-019-0981-5.
APA：
Sun, Jian,Ding, Huiguo,Chen, Guofeng,Wang, Guiqiang,Wei, Lai...&Hou, Jinlin.(2019).Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.BMC GASTROENTEROLOGY,19,
MLA：
Sun, Jian,et al."Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China".BMC GASTROENTEROLOGY 19.(2019)

相关文献

[1]Long-term Follow-up Study of COVID-19 [2]Peg-interferon alpha induces CD56(bright) natural killer cell mediated reduction of HBsAg in entecavir treated chronic Hepatitis B patients [3]Longitudinal Changes in Characteristics of COVID-19 Survivors and Their Long-term Follow-up Study [4]Long-term chest CT follow-up in COVID-19 Survivors: 102-361 days after onset [5]Childhood-Onset Myasthenia Gravis Patients Benefited from Thymectomy in a Long-Term Follow-up Observation [6]Sustained immune control in HBeAg-positive chronic hepatitis B patients who switched from long-term entecavir therapy to peginterferon alfa-2a (40KD): 1-year follow-up of the OSST study [7]Case Report: Fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up [8]Long-term follow-up of dynamic brain changes in patients recovered from COVID-19 without neurological manifestations [9]Selective peripheral denervation for the treatment of spasmodic torticollis: long-term follow-up results from 648 patients [10]A Long-Term Follow-Up of a New Surgery Method: Laparoscope-Assisted Heart-Shaped Anastomosis for Hirschsprung's Disease

资源点击量：589 今日访问量：0 总访问量：441 更新日期：2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）